Viemed Posts Record Q2 Revenue of $78.1M and Lifts the Low End of Its 2026 Revenue Outlook
VMD sits 85% above its 52-week low of $5.93.
Summary
Viemed reported Q2 2026 revenue of $78.1 million, up 24% year-over-year, and raised the low end of its full-year revenue guidance. The company also repurchased $5.1 million of shares and achieved record patient counts across all segments.
Key Events · Earnings and Guidance · VMD
-
Record Q2 Revenue
Revenue reached $78.1 million, a 24% increase year-over-year and 3.6% sequentially, driven by a record ventilator patient census of 12,635 and strong growth in PAP and sleep resupply.
-
Updated 2026 Guidance
Full-year revenue guidance was raised to $314M-$320M (low end up from $312M). Adjusted EBITDA guidance was revised to $64M-$68M (from $65M-$69M), and net capex was lowered to 8.5%-10.0% of revenue.
-
Share Repurchase
The company repurchased 530,802 shares for $5.1 million at an average price of $9.65 per share, below the current $11.00, signaling management's confidence in intrinsic value.
-
Strong Cash Generation
Operating cash flow reached $15.9 million and free cash flow $8.6 million during the quarter, with trailing twelve-month free cash flow of $34.4 million.
Analysis · VMD · Industrial Applications And Services
Record quarterly revenue was fueled by an all-time high ventilator patient census and robust growth in PAP and sleep resupply. Although net income and Adjusted EBITDA edged lower year-over-year, the company raised the low end of its full-year revenue guidance, signaling confidence in sustained momentum. A $5.1 million share buyback at an average price of $9.65—well below the current $11.00—highlights disciplined capital allocation and management's view that the stock was undervalued. The revised guidance also points to a shift toward less capital-intensive revenue, which should strengthen free cash flow generation.
At the time of this filing, VMD was trading at $11.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.2M. The 52-week trading range was $5.93 to $12.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.